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Diabetes and cancer are common, chronic, and potentially fatal diseases that frequently
co-exist. Observational studies clearly indicate that the risk of several types of cancer
is increased in diabetic patients and a number of cancer types have shown a higher
mortality rate in patients with hyperglycemic associated pathologies. This scenario could
be due, at least in part, to a lower efficacy of the cancer treatments which needs to be
better investigated. Here, we evaluated the effects of a prolonged exposure to high
glucose (HG) to the response to chemotherapy on human colon adenocarcinoma HT29
and LOVO cell lines. We observed that hyperglycemia protected against the decreased
cell viability and cytotoxicity and preserved from the mitochondrial DNA lesions induced
by doxorubicin (DOX) and 5-fluorouracil (5-FU) treatments by lowering ROS production.
In HT29 cells the amount of intracellular DOX and its nuclear localization were not
modified by HG incubation in terms of Pgp, BCRP, MRP1, 5 and 8 activity and gene
expression. On the contrary, in LOVO cells, the amount of intracellular DOX was
significantly decreased after a bolus of DOX in HG condition and the expression and
activity of MPR1 was increased, suggesting that HG promotes drug chemoresistance
in both HT29 and LOVO cells, but in a different way. In both cell types, HG condition
prevented the susceptibility to apoptosis by decreasing the ratio Bax/Bcl-2 and Bax/Bcl-
XL and diminished the level of cytosolic cytochrome c and the cleavage of full length
of PARP induced by DOX and 5-FU. Finally, hyperglycemia reduced cell death by
decreasing the cell percentage in sub-G1 peak induced by DOX (via a cell cycle
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arrest in the G2/M phase) and 5-FU (via a cell cycle arrest in the S phase) in HT29
and LOVO cells. Taken together, our data showed that a prolonged exposure to HG
protects human colon adenocarcinoma cells from the cytotoxic effects of two widely
used chemotherapeutic drugs, impairing the effectiveness of the chemotherapy itself.
Keywords: hyperglycemia, chemoresistance, doxorubicin, 5-fluorouracil, cytotoxicity, cell damage, colon
adenocarcinoma
INTRODUCTION
Antineoplastic drugs are an important therapeutic tool for
cancer patients, but the development of multidrug resistance
(MDR) may result in failure of the treatment, leading to tumor
relapse and further progression. One of the mechanisms of
MDR is the overexpression of the ATP binding cassette (ABC)
transporters, such as P-glycoprotein (Pgp) and other MDR-
related proteins (e.g., BCRP and MRPs), that actively extrude
anticancer drugs, such as anthracyclines (e.g., doxorubicin,
DOX), taxanes, Vinca alkaloids, epipodophyllotoxins, topotecan,
mitomycin C (Comerford et al., 2002; Gottesman et al., 2002),
leading to a decrease of the accumulation of intracellular
chemotherapeutics and of their cytotoxic effects (Riganti
et al., 2008, 2009; Doublier et al., 2012; Marin et al., 2016).
Furthermore, MDR can develop by other numerous mechanisms
including activation of detoxifying systems, changes in the
expression/function of the molecular targets of anticancer
drugs, enhanced ability of cancer cells to repair anticancer
drug-induced DNA damage, and decreased and up-regulated
expression/function of pro- or anti-apoptotic factors (Stattin
et al., 2007).
The most recent International Diabetes Federation’s estimates
indicate that 12.8% of adults – 382 million people worldwide in
2016 – have diabetes, and the number of people with the disease
is set to rise beyond 592 million in less than 25 years, whereas
1.5 million people die from this disease every year (WHO, 2016).
Hyperglycemia is often a consequence of a Western lifestyle
that is associated with metabolic syndrome and type-2 diabetes
or obesity, and high levels of glucose may be present in the
blood for many years before the onset of overt diabetes (which
may not appear at all throughout the life) (Atlas Website,
2014).
Hyperglycemia is a pathophysiological condition
characterized by high blood glucose concentration that is not
only a key pathological factor involved in diabetic complications
(Nathan et al., 2013), but also it has been shown to predispose
to cancer development (Biadgo et al., 2016) and progression
(Duan et al., 2014). Indeed, multiple meta-analyses and large
cohort studies support an association between hyperglycemia
and increased cancer risk, especially for the breast, colorectal,
pancreas, endometrium, and urinary tract cancer (Arcidiacono
et al., 2012). It is becoming clear that sustained hyperglycemia is
related not only to cancer incidence (Orgel and Mittelman, 2013),
but also to cancer response to chemo-radiotherapy treatment
(Meyerhardt et al., 2003; Caudle et al., 2008).
Even if several signaling pathways have been evaluated
with respect to their involvement in drug resistance and
hyperglycemia, gaining a better understanding of the
mechanisms underlying the failure of cancer treatment may
improve the drug efficacy in this condition.
In the present study, we evaluate the effects of a prolonged
exposure to high glucose (HG) in the response to two
chemotherapeutic drugs [DOX and 5-fluorouracil (5-FU)] on
human colon adenocarcinoma (HT29 and LOVO cell lines).
MATERIALS AND METHODS
Cells and Reagents
Human colon adenocarcinoma (HT29 and LOVO cell lines)
obtained from the American Type Culture Collection (Rockville,
MD, United States) were grown as a subconfluent monolayer in
DMEM and F12/DMEM medium, respectively, containing 2 mM
L-glutamine, 1% (v/v) antibiotic/antimycotic solution, and 10%
(v/v) fetal bovine serum (FBS).
Unless otherwise specified, reagents were purchased from
Sigma-Aldrich (Milan, Italy), whereas plastic ware was from
Falcon (Becton Dickinson, Franklin Lakes, NJ, United States).
Experimental Conditions
Different types of cells were cultured up to 12 weeks in
medium containing normal glucose (control cells, G, 5.56 mM
equal to 100 mg/dL) or HG (25 mM equal to 450 mg/dL).
Mannitol (M, 25 mM) was used as osmotic control cells.
Glucose concentrations of 5.56 mM and 25 mM, chosen in
this study, correspond to glycemia in fasting healthy individuals
and to hyperglycemia encountered in diabetic patients poorly
controlled.
As preliminary experiments, we evaluated one-weekly
lactate dehydrogenase (LDH) leakage and DOX intracellular
accumulation up to 12 weeks in HG condition (data not shown).
Given the similar results observed after 1 week and after the
following experimental points, the experimental conditions have
been standardized using cells cultured in very HG not less than
7 days (HG ≥ 7 days).
When required, cells were incubated for 24, 48, or 72 h before
analysis with different doses of DOX or of 5-FU. 5-FU was chosen
as one of the main elective drugs for colorectal cancer treatment,
whereas DOX, used as drug for solid tumors, was also easily
detectable in our experimental approaches.
Cell Viability
Cells were grown in G and HG ≥ 7 days, treated for 24, 48,
or 72 h, respectively, with chemotherapeutic agents at scalar
concentrations (from 0.05 µmol/L to 10 µmol/L for DOX or
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from 1 µmol/L to 50 µmol/L for 5-FU, then stained for 1 h at
37◦C in culture medium containing Neutral Red solution, washed
three times with phosphate-buffered saline solution (PBS) and
rinsed with stop buffer (1:1 of 4.02 g trisodium citrate in 153 mL
H2O, 0.8 mL HCl 0.1 N in 86 mL H2O and 25 ml of 95% v/v
methanol), as described (Gelsomino et al., 2013). The absorbance
was read at 540 nm and the cell viability was evaluated by
measuring the percentage of cells stained with neutral red dye,
as reported previously (Repetto et al., 2008). The viability of
untreated cells was considered 100%; the results were expressed
as percentage of viable cells in each experimental condition
versus untreated cells. The inhibitory concentration 50 (IC50),
defined as the concentration of each drug able to decrease
the cell viability by 50%, was calculated with the CompuSyn
software1.
Lactate Dehydrogenase (LDH) Leakage
For LDH leakage measurement, cells were grown in G and
HG ≥ 7 days, then after 24 and 48 h of incubation with
DOX (from 0.5 µmol/L to 10 µmol/L) or after 72 h of
5-FU (25 and 50 µmol/L), the extracellular medium was
withdrawn and centrifuged at 12,000 × g for 30 min to
remove cellular debris. Cells were washed with PBS, detached
with trypsin/EDTA (0.05/0.02% v/v), resuspended in 1 ml of
PBS and sonicated on ice with two 10-s bursts. LDH activity
was measured in the extracellular medium and in the cell
lysate, as previously described (Beutler, 1971; Riganti et al.,
2006) to verify the cytotoxic effect of chemotherapeutic agents.
Both intracellular and extracellular enzyme activities, measured
spectrophotometrically as absorbance variation at 340 nm
(37◦C), were expressed as nmol NADH oxidized/min/dish;
then extracellular LDH activity was calculated vs. the total
(intracellular+ extracellular) LDH activity in the dish.
Measurement of Total Cellular and
Mitochondrial ROS Production
Cells were grown in G and HG ≥ 7 days, then, after 24 h
incubation in the absence or presence of 5 and 10 µM DOX
or 25 and 50 µM 5-FU, cells were divided into two aliquots:
one aliquot, to detect total cellular ROS production, has been
resuspended in fresh appropriate medium; the other one, to
detect mitochondrial ROS production, has been used to prepare
mitochondrial fraction (see details in “Materials and Methods,”
section “Cytochrome c Western Blot Analysis”). Total and
mitochondrial lysates were loaded for 15 min with 10 µM
2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA). DCFH-
DA is a cell-permeable probe that is cleaved intracellularly by
non-specific esterases to form DCFH, which is further oxidized
by ROS to form the fluorescent compound dichlorofluorescein
(DCF). After the incubation, cells were washed twice with
PBS to remove excess probe, and total and mitochondrial
DCF fluorescence were determined at an excitation wavelength
of 504 nm and an emission wavelength of 529 nm, using
a Packard EL340 microplate reader (Bio-Tek Instruments,
Winooski, VT, United States). The fluorescence value was
1http://www.combosyn.com
normalized to the protein content and expressed as RFU/mg
cellular proteins or mitochondrial proteins (Bergandi et al.,
2010).
Mitochondrial DNA (mtDNA) Damage
Analysis
Cells were grown in G and HG ≥ 7 days, then incubated
with DOX (5 and 10 µM for 24 h) or 5-FU (25 and 50
µM for 72 h) and washed with ice-cold PBS twice. Total
DNA was purified using the Extract-NAmpTM polymerase
chain reactions from tissue kit containing all the reagents
needed to rapidly extract and amplify human genomic DNA.
Briefly, 10 µl of cells was mixed with 20 µl of the extraction
solution and the mixture was incubated at room temperature
for 5 min. After adding 180 µl of the neutralization solution,
the extract was ready for determine the mtDNA integrity by
qRT-PCR and the lesion rate by semi-long run rt-PCR (SLR
rt-PCR).
The qRT-PCR was carried out as described by Yakes
and Van Houten (1997) and Yang et al. (2014) amplifying
equal amounts of total DNA isolated from differentially
treated cells, employing 16.2 kb mitochondrial and 10.4
kb nuclear DNA fragments: 16.2.F 5′-TGAGGCCAAA
TATCATTCTGAGGGGC-3′, 16.2.R 5′-TTTCATCATGCGGAG
ATGTTGGATGG-3′; 10.4.F 5′-TGGGATTACACGTGTGAAC
CAACC-3′, 10.4.R 5′-GCTCTACCCTCTCCTCTACCGRCC-3′.
Quantitative PCR amplification of a 10.4 kb fragment from
the nuclear globin gene and a 16.2 kb fragment from the
mitochondrial genome was used to detect mtDNA integrity.
The SLR rt-PCR amplifications were conducted in according
to Rothfuss et al. (2010) in CFX96 TouchTM Real-Time PCR
Detection System (Bio-Rad, Hercules, CA, United States), and
the amplification was monitored and analyzed by measuring
the intercalation of the fluorescent dye to double-stranded DNA
supplied by iTaqTM Universal SYBR R© Green Supermix (Bio-Rad)
according to the manufacturer’s instructions.
To compare the levels of DNA lesion in each tested region of
the mitochondrial genome, two mtDNA fragments of different
lengths [long fragments (L) ranging from 972 to 1037 bp and
small fragments (S) from 54 to 87 bp, respectively], located
in the same mitochondrial genomic region were used. To
quantify the mitochondrial lesion frequency the four 1 kb
sized mtDNA regions selected for the SLR rt-PCR approach
were the following [(a) D-loop region, chrM:16021+423,
(b) ATPase region, chrM:8204+9203, (c) ND4/5 region,
chrM:12050+13049, (d) ND1/2 region, chrM:3962+4998].
The specific oligonucleotides were: for short amplicon AS1.F/R
(5′-CCCTAACACCAGCCTAACCA-3′ and 3′-AAAGTGCATAC
CGCCAAAAG-5′), BS1.F/R (5′-CATGCCCATCGTCCTAGA
AT-3′ and: 3′-ACGGGCCCTATTTCAAAGAT-5′), CS1.F/R
(5′-TCCAACTCATGAGACCCACA-3′ and 3′-TGAGGCTTGG
ATTAGCGTTT-5′), DS1.F/R (5′-ACTACAACCCTTCGCTGA
CG-3′ and 3′-GCGGTGATGTAGAGGGTGAT-5′) and for long
amplicon AL4.F/AS1.R (5′-CTGTTCTTTCATGGGGAAGC-3′
and 3′-AAAGTGCATACCGCCAAAAG-5′), BL1.F/R (5′-CAT
GCCCATCGTCCTAGAAT-3′ and 3′-TGTTGTCGTGCAGGT
AGAGG-5′), CL1.F/R (5′-CACACGAGAAAACACCCTCA-3′
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and 3′-CTATGGCTGAGGGGAGTCAG-5′), DL1.F/R (5′-CCCT
TCGCCCTATTCTTCAT-3′ and 3′-GCGTAGCTGGGTTTGGT
TTA-5′). The reaction mix consisted of 1 µl iTaqTM Universal
SYBR R© Green Supermix, 500 nM each forward and reverse
primer (specific for the long and the short amplicon) and the
equivalent quantities of template DNA (3 ng of total DNA) in 10
µl total volume. The cycling conditions include a pre-incubation
phase of 10 min at 95◦C followed by 40 cycles of 10 s 95◦C, 10 s
60◦C, and 10 s 72◦C (for small fragments) or 50 s 72◦C (for large
fragments). Each sample was assayed in triplicate, fluorescence
was continuously monitored versus cycle numbers and crossing
point values were calculated by the CFX96 TouchTM software
(Bio-Rad). The PCR conditions for the different fragments were
optimized to achieve similar amplification efficiencies required
to compare different amplicons. The product specificity was
monitored by melting curve analysis and product size was
visualized on agarose gel by electrophoresis (data not shown).
For the quantification of damage in each mtDNA region,
the crossing point (Cp) of isolated mitochondrial DNA from
untreated sample was taken as reference. For each of the four
mtDNA regions the difference in the crossing point 1Cp (long
fragment/small fragment) was used as a measure of the relative
mitochondrial lesion frequency with the 2−11CT method in
correlation to the amplification size of the long fragment and
expressed as lesion per 10 kb DNA of each mtDNA region by
including the size of the respective long fragment and displayed as
average of at least three independent experiments (Rothfuss et al.,
2010).
Lesion rate [Lesion per 10 kb DNA] = (1–2 − (1 long − 1
short))× 10000 [bp]/size of long fragment [bp].
Doxorubicin Accumulation
Before every test, cells were grown in G and HG ≥ 7 days and
incubated with DOX (5 and 10 µM for 24 h or 0.5 and 1 µM
for 48 h), then washed twice in PBS, and cells were scrapered
and collected. Cells were centrifuged for 30 s at 13,000 rpm
(4◦C) and resuspended in 700 µl of a 1:1 mixture of ethanol/0.3
N HCl. Fifty microliters of cell suspension were sonicated on
crushed ice with two 10-s bursts (Labsonic sonicator, 100 W)
and used for measurement of cellular proteins; the remaining
part was checked for the DOX content using a Perkin-Elmer
LS-5 spectrofluorimeter (Perkin Elmer). Excitation and emission
wavelengths were 475 and 553 nm, respectively. A blank was
prepared in the absence of cells in every set of experiments and its
fluorescence was subtracted from that obtained in the presence of
cells (Riganti et al., 2011). Fluorescence was converted in nmol of
DOX per milligram of cellular proteins, using a calibration curve
prepared previously.
Preparation of Samples for RP-HPLC
Quantification of Doxorubicin and
5-Fluorouracil and Their Metabolites
Cells were grown in G and HG ≥ 7 days and then incubated
with DOX (5 and 10 µM for 24 h) washed twice in ice-
cold PBS and resuspended in 500 µl of PBS. Cellular samples
derived from DOX incubation were diluted 1:1 with acetonitrile
0.1% HCOOH; the mixture was sonicated, centrifuged for
10 min at 2150 g, filtered (0.45 µm PTFE) and analyzed
by RP-HPLC. HPLC analyses were performed with a HP
1200 chromatograph system (Agilent Technologies, Palo Alto,
CA, United States) equipped with a quaternary pump (model
G1311A), a membrane degasser (G1322A), a multiple wavelength
UV-vis detector (MWD, model G1365D), a thermostated column
compartment (model G1316A), and fluorescence detector (FLD,
model G1321A) integrated in the HP1200 system. Data analysis
was performed using a HP ChemStation system (Agilent
Technologies). Samples were analyzed according to Sakai-Kato
et al. (2010) on a Tracer Excel 120 ODSB column (25 × 0.46, 5
µm) (Teknokroma). The injection volume was 20µL (Rheodyne,
Cotati, CA, United States). The mobile phase consisting of
acetonitrile (A) and 0.1% HCOOH (B) at flow-rate = 1.0 mL/min
with gradient conditions: 35% A until 5 min, from 35 to 80%
A between 5 and 10 min, 80% A between 10 and 20 min, and
from 80 to 35% A between 20 and 25 min. The column effluent
was monitored by MWD at 234 and 480 nm referenced against
a 800 nm wavelength. Data analysis was performed with Agilent
ChemStation. This method simultaneously determines DOX and
its main metabolites in HT29 and LOVO cells. The values
obtained from integration of the peak of DOX were interpolated
in a calibration curve obtained using standard solutions of DOX
at 0.1 µM to 50 µM (r2 = 0.996).
The micromolar concentration value was normalized to the
protein content and expressed as nmol DOX or metabolites/mg
cell proteins.
Cellular samples derived from 5-FU incubation (25 and 50
µM for 24, 48, and 72 h) were added with acetonitrile (4:1, v/v);
the mixture was sonicated, centrifuged for 10 min at 2150 × g,
filtered (0.45µm PTFE) and analyzed by liquid chromatography-
electrospray ionization-tandem mass spectrometry (LC-ESI-MS)
analyses. LC-ESI- MS analyses were performed with an Acquity
Ultra Performance LCTM, Waters Corporation, Milford, MA,
United States, equipped with BSM, SM, CM, and PDA detector.
All the chromatographic separations were performed on Aquasil
C18 column (20 × 0.46, 5 µm) (Thermo) as a stationary phase.
Aliquots of 5 µL were injected onto the system and eluted
with a mobile phase (flow rate, 0.5 mL/min) consisting of
acetonitrile, and 0.1% HCOOH 5/95 v/v. The eluate was injected
into the electrospray ion source (ESI), and monitored using
Micromass Quattro microTM API ESCi multi-mode ionization
Enabled as detector. MS spectra were acquired and processed
using MassLynx software. The operating conditions on the triple
quadruple mass spectrometer were as follows: negative mode;
drying gas (nitrogen) heated at 350◦C at a flow rate of 800 L/h;
nebulizer gas (nitrogen) at 80 L/h; capillary voltage in positive
mode at 3000 V; cone voltage at 40 V. The molecular ion [M-
H]− was employed for quantitative measurements of analyte.
The values obtained from integration of the peak of compound
were interpolated in a calibration curve obtained using standard
solutions at 0.01–20 µM. The amount of compound was
expressed as nmol/mg cell proteins.
5-FU content in cellular culture medium was assessed after
72 h incubation in the presence of HT29 and LOVO cells.
Supernatant was diluted 1:1 with acetonitrile; the mixture was
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sonicated, centrifuged for 10 min at 2150 × g, filtered (0.45
µm PTFE) and analyzed by RP-HPLC. HPLC analyses were
performed with a HP 1200 chromatograph system previously
described.
Samples were analyzed according to Carli et al. (2009) on an
Aquasil C18 column (20 × 0.46, 5 µm) (Thermo); the injection
volume was 20µL (Rheodyne, Cotati, CA, United States). Elution
was performed under gradient conditions, employing a mobile
phase consisting of acetonitrile (A) and 0.1% HCOOH (B): 0%
A until 8 min, from 0 to 10% A between 8 and 15 min, 10%
A between 15 and 20 min, and from 10 to 0% A between 20
and 25 min. The flow-rate was 1.0 ml/min and the UV detector
was set at 270 nm referenced against a 800 nm wavelength. Data
analysis was performed with Agilent ChemStation. The values
obtained from integration of the peak of 5-FU and metabolites
were interpolated in calibration curves obtained using standard
solutions of the analytes at 0.1 µM to 50 µM (r2 = 0.995). The
HPLC value was normalized to the protein content and expressed
as nmol 5-FU/mg cell proteins.
Immunofluorescence Staining
0.5× 106 cells, incubated in the experimental conditions reported
previously, were grown on sterile glass coverslips, rinsed with
PBS, fixed with 4% w/v paraformaldehyde (diluted in PBS) for
15 min, washed three times with PBS and incubated with 4′,6-
diamidino-2-phenylindole dihydrochloride (DAPI, diluted 1:
20000) for 3 min at room temperature in the dark. Fluorescently
labeled cells were washed three times with PBS and once
with water, then the slides were mounted with 4 µl of Gel
Mount Aqueous Mounting and examined with a Leica DC100
fluorescence microscope (Leica Microsystems GmbH, Wetzlar,
Germany). For each experimental point, a minimum of five
microscopic fields were examined.
Pgp and MRP Activities
The efflux of rhodamine 123, a substrate of Pgp and MRP, was
taken as an index of Pgp plus MRP activity. Cells were grown
in G and HG ≥ 7 days, then washed with fresh PBS, detached
with cell dissociation solution and resuspended at 5 × 105
cells/mL in 1 mL of DMEM medium containing 5% FBS. The
samples were maintained at 37◦C for 20 min in the presence of
1 µg/mL rhodamine 123. After this incubation time, cells were
washed and resuspended in 500 µl of PBS, and the intracellular
rhodamine content, which is inversely related to its efflux, was
analyzed for the rhodamine content, using a PerkinElmer LS-
5 spectrofluorimeter. Excitation and emission wavelengths were
507 and 527 nm, respectively. An aliquot of sample was used
for the determination of the intracellular proteins. A blank was
prepared in the absence of cells in each set of experiments, and
its fluorescence was subtracted from the one measured in each
sample. Fluorescence was converted in % of rhodamine 123/mg
of cell proteins using a calibration curve prepared previously.
BCRP Activity
The efflux of Hoechst 33342, a specific substrate of BCRP, was
taken as an index of BCRP activity. Cells were grown in G and
HG ≥ 7 days, then washed with PBS and resuspended in 500 µL
of DPBS buffer (129 mM NaCl, 2.5 mM KCl, 7.4 mM Na2HPO4,
1.3 mM KH2PO4, 1 mM CaCl2, 0.7 mM MgSO4, 5.3 mM glucose;
pH 7.4), in the presence of 50 µM Hoechst 33342 for 15 min at
37◦C. Then 400 µl of stop solution (210 mM KCl, 2 mM Hepes;
pH 7.4) was added and cells were lysed with 100 µl of 0.1% v/v
Triton-X 100, dissolved in 0.3% v/v NaOH.
An aliquot of sample was used for the determination
of the intracellular proteins, and the remaining part was
analyzed for the Hoechst content, using a PerkinElmer LS-5
spectrofluorimeter. Excitation and emission wavelengths were
370 and 450 nm, respectively. A blank was prepared in the
absence of cells in each set of experiments, and its fluorescence
was subtracted from the one measured in each sample.
Fluorescence was converted in % of Hoechst/mg of cell proteins
using a calibration curve prepared previously.
Real-Time Polymerase Chain Reaction
(qRT-PCR)
Before every test, cells were grown in G and HG ≥ 7 days
and then washed with PBS. Total RNA was extracted with
TRIzol R© (Invitrogen, Thermo Fisher Scientific, Waltham, MA,
United States). One µg of total RNA were reversely transcribed
into cDNA, in a final volume of 20 µl, using the iScriptTM
cDNA Synthesis Kit (Bio-Rad, Hercules, CA, United States)
according to the manufacturer’s instructions. The RT-PCR
primers were designed with NCBI/Primer-BLAST. Quantitative
PCR was carried out in a final volume of 20 µl using the iTaqTM
Universal SYBR R© Green Supermix (Bio-Rad, Hercules, CA,
United States) with specific primers for the quantitation of
ATP-binding cassette, sub-family C (CFTR/MRP) member 1
(ABCC1) (MRP1, 5′-TCTGGTCAGCCCAACTCTCT-3′ and
5′-CCTGTGATCCACCAGAAGGT-3′), ATP-binding cassette,
sub-family C (CFTR/MRP) member 5 (ABCC5) (MRP5, 5′-CC
CAGGCAACAGAGTCTAACC-3′ and 5′-CGGTAATTCAATG
CCCAAGTC-3′), ATP-binding cassette, sub-family C (CFTR/
MRP) member 8 (ABCC8) (MRP8, 5′-TCTGCGACCTTCTT
GTTTGG-3′ and 5′-TCAGTACAGCATTTGCAACACTT-3′),
ATP-binding cassette, sub-family G ABCG2 (BCRP, 5′-AGCTG
CAAGGAAAGATCCAA-3′ and 5′-TCCAGACACACCACGG
ATAA-3′), ATP-binding cassette, sub-family B (MDR/TAP)
member 1 (ABCB1) (Pgp, 5′-GACTGAGCCTGGAGGTGAAG-
3′ and 5′-CCACCAGAGAGCTGAGTTCC-3′), topoisomerase
II alpha (TOPO II alpha, 5′-GCCCTCAAGAAGATGGTGTG-
3′ and 5′-TGCCAATGTAGTTTGTTTCTTG-3′) and beta
2-microglobulin (β2M, 5′-AGCAAGGACTGGTCTTTCTATC
TC-3′ and 5′-ATGTCTCGATCCCACTTAACTA-3′) genes.
PCR amplification was 1 cycle of denaturation at 95◦C for
30 s, 40 cycles of amplification including denaturation at 95◦C
for 30 s and annealing/extension at 60◦C for 1 min. Standard
curves, with serially diluted solutions (1:1; 1:10; 1:100; and
1:1000 for MRP1/5/8 and BCRP genes and 1:1; 1:10; 1:100
for Pgp) of cDNAs obtained as a template for each gene,
were included in each PCR and amplified by target-specific
primer sequence to quantify the PCR baseline subtracted relative
fluorescence unit. The threshold cycle (Ct) reflects the cycle
number at which the fluorescence generated within a reaction
crosses the threshold line. The quantification of each sample
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was performed comparing each PCR gene product with B2M,
used as reference gene to normalize the cDNA in different
samples, and expressed in arbitrary units, using the Bio-Rad
Software Gene Expression Quantitation (Bio-Rad Laboratories),
calculated using the 2−11CT method (Livak and Schmittgen,
2001). Analyzed transcripts exhibited high linearity amplification
plots (r > 0.98) and similar PCR efficiency (84% for MRP1,
83.4% for MRP5, 85.6% for MRP8, 95% for BCRP, 83.8% for
Pgp, 92% for TOPO II alpha, and 94% for β2M), confirming
that the expression of each gene could be directly compared.
The specificity of PCRs was confirmed by melt curve analysis.
Non-specific amplifications were never detected.
Bcl-2, Bcl-XL, Bax, PARP Western Blot
Analysis
Cells were grown in G and HG ≥ 7 days and then incubated
with DOX (5 and 10 µM for 24 h) or 5-FU (25 and 50 µM
for 72 h). Cells were collected and washed twice in PBS, then
lysed for 1 h in ice-cold lysis buffer (50 mM Tris–HCl, 150 mM
NaCl, 5 mM EDTA, pH 7.4 supplemented with the protease
inhibitor cocktail set III (Sigma-Aldrich, Milan, Italy), 1 mM
sodium orthovanadate, 1 mM phenylmethanesulfonyl fluoride,
1 mg/ml aprotinin, 50 mM sodium fluoride, 1% Triton X-100).
Cell lysates were then centrifuged for 15 min at 13,000 rpm at
4◦C (Poornima et al., 2014). Proteins were subjected to SDS-
PAGE and subsequently transferred to PVDF membrane. The
blots were blocked with 5% non-fat milk in PBS at RT for 1 h
and incubated overnight with the following antibodies: mouse
anti-Bcl-2 antibody (1–2 µg/ml in PBS-BSA 1%, from Thermo
Fisher Scientific, Waltham, MA, United States), mouse anti-
Bcl-XL antibody (diluted 1:250 in PBS-BSA 1%, from Thermo
Fisher Scientific), mouse anti-Bax antibody (diluted 1:100 in
PBS-BSA 1%, from Thermo Fisher Scientific), mouse anti-Poly-
(ADP-Ribose)-Polymerase full length antibody (diluted 1:500 in
PBS-BSA 1%, from Roche, Basel, Swiss) and mouse anti-GAPDH
antibody (diluted 1:1000 in PBS-BSA 1% from Sigma-Aldrich,
Italy). The latter antibody was used to check the equal protein
loading in extracts. After an overnight incubation, the membrane
was washed with 0.1% v/v PBS-Tween and subjected for 1 h to
a peroxidase-conjugated anti-mouse secondary antibody (diluted
1:5000 in 5% w/v PBS-Tween with milk, Bio-Rad Laboratories,
Hercules, CA, United States). The membrane was washed again
with PBS-Tween, and proteins were detected and quantified by
ChemiDocTM MP System (Bio-Rad Laboratories, Hercules, CA,
United States). Densitometric analysis was carried out using
ImageJ software2.
Cytochrome c Western Blot Analysis
Cells were grown in G and HG ≥ 7 days and then incubated
with DOX (5 and 10 µM for 24 h) or 5-FU (25 and 50
µM for 72 h). The cell supernatant was collected, centrifuged
at 4,000 rpm for 2 min at 4◦C and, after washing with ice-
cold PBS twice, resuspended in mitochondrial lysis buffer A
(50 mM Tris, 100 mM KCl, 5 mM MgCl2, 1 mM EDTA,
ATP 1.8 mM, pH = 7.2). 5 × 106 cells were washed twice
2http://rsbweb.nih.gov/ij/
in ice-cold PBS, then added to the pellet derived from cell
supernatant and resuspended in 500 µl of mitochondrial lysis
buffer A, supplemented with the protease inhibitor cocktail set
III (Sigma-Aldrich, Milan, Italy), 1 mM phenylmethylsulfonyl
fluoride and 2.5 mM sodium fluoride. Samples were clarified by
centrifuging at 2,000 rpm for 2 min at 4◦C, and the supernatant
was collected and centrifuged at 13,000 rpm for 5 min at 4◦C.
The supernatant (cytosolic fraction) was aliquoted and the pellet
containing mitochondria (mitochondrial fraction) was washed
in 500 µl buffer A and resuspended in 250 µl mitochondrial
resuspension buffer B (250 mM sucrose, 15 mM K2HPO4,
2 mM MgCl2, 0.5 mM EDTA, 5% w/v BSA). The aliquot of
mitochondrial fraction was sonicated, used for the measurement
of protein concentration and stored at −80◦C until the use. Ten
micrograms from mitochondrial extracts were subjected to 15%
SDS-PAGE, transferred to PVDF membrane and probed with the
following antibodies: mouse anti-cytochrome c antibody (diluted
1:250 in PBS-BSA 1%, from BD Biosciences, San Jose, CA,
United States) and mouse anti-β-tubulin (diluted 1:500 in PBS-
BSA 1% from Santa Cruz Biotechnology Inc., Santa Cruz, CA,
United States). The latter antibody was used to check the equal
protein loading in mitochondrial extracts. After an overnight
incubation, the membrane was washed with 0.1% v/v PBS-Tween
and subjected for 1 h to a peroxidase-conjugated anti-mouse
secondary antibody (diluted 1:5000 in 5% w/v PBS-Tween with
milk, Bio-Rad Laboratories, Hercules, CA, United States). The
membrane was washed again with PBS-Tween, and proteins
were detected and quantified by ChemiDocTM MP System (Bio-
Rad Laboratories, Hercules, CA, United States). Densitometric
analysis was carried out using ImageJ software (see footnote 2).
Cell Cycle Analysis
Cells were grown in G and HG ≥ 7 days, then, after 24 h
incubation in the absence or presence of 5 and 10 µM DOX or
after 72 h with 25 and 50 µM 5-FU, cells were collected, fixed in
70% cold ethanol for 30 min on ice and centrifuged at 1,800 rpm
for 10 min. Cells were washed with PBS, then 1 × 106 cells/ml
were resuspended in 1 ml PBS and incubated in propidium iodide
solution (20 µg/ml propidium iodide and 0.2 mg/ml RNAseA
in PBS) for 1 h at room temperature. Cellular DNA content
was analyzed by Coulter EPICS XL (CoulterCorp, Hialeah, FL,
United States) flow cytometry and to perform the analysis only
on intact single cells, an electronic gate for doublet and clump
exclusion was used (Lanza et al., 1996; Catalano et al., 2009). To
quantify the relative proportions of the various cell cycle phases,
a Multicycle software (Phoenix Flow Systems, San Diego, CA,
United States) was used.
Topoisomerase II Alpha Assay
The in vitro activity of topoisomerase II alpha was measured
using the Topoisomerase II Assay Kit plasmid based
(Topogen Inc., Port Orange, FL, United States), following
the manufacturer’s instructions.
Cells were grown in G and HG ≥ 7 days, then incubated
with DOX 5 and 10 µM for 24 h and washed with ice-cold PBS
twice. The cells were scraped up in PBS, collected, centrifuged at
800× g for 3 min at 4◦C. The pellet containing the same amount
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of cell proteins was resuspended in 5 ml of ice-cold TEMP buffer
(10 mM Tris−HCl, pH 7.5, 1 mM EDTA, 4 mM MgCl2, 0.5 mM
PMSF), centrifuged again at 800 × g for 3 min at 4◦C and
resuspended in 3 ml of ice-cold TEMP buffer. After 10 min on
ice, cells were dounced in tight fitting homogenizer with six to
eight strokes. The nuclei were then pelleted by centrifugation at
1,500 × g for 10 min and the nuclear pellet was resuspended
in a small volume (no more than four pellet volumes) of TEP
(TEMP buffer without MgCl2) and an equal volume of 1 M NaCl,
left on ice for 30–60 min and then spin in a cold microfuge at
13,000 × g for 15 min. The supernatants containing Topo II
activity were assessed using kDNA provided in the TopoGEN
Topo II assay kit (Topogen Inc., Port Orange, FL, United States).
The assay measures the Topo II-specific enzymatic conversion of
highly catenated kDNA into decatenated DNA. 1–2µg of nuclear
extracts or purified human Topo II alpha (Topo GEN), used as a
positive control, were added for 30 min at 37◦C to a standard
reaction mixture consisting in 5X complete reaction buffer and 1
µl kDNA (250–500 ng/µl) in a final volume of 20µl. The reaction
was stopped with 4 µl stop buffer 5X. The reaction products
together with linear and decatenated kDNA used as markers were
resolved on a 1% w/v agarose gels for 15 min at 100V and stained
with 0.01% v/v ethidium bromide. Gels were documented using
Gel Doc 2000 ChemiDoc (Bio-Rad, Hercules, CA, United States)
and analyzed using the Quantity One software (Bio-Rad). The
appearance of a band corresponding to decatenated plasmid,
that migrates rapidly into agarose gel as opposed to the circular
kDNA, was taken as an index of active cellular topoisomerase II.
The assay was linear between 0.25 and 1 U of purified Topo II
alpha (1 U defined as the amount of enzyme that decatenates 0.2
µg of kDNA in 15 min at 37◦C), and between 0.063 µg and 2 µg
total protein of a reference nuclear extract.
Statistical Analysis
Data were expressed as mean ± SEM of the mean. The
results were checked for normal distribution and analyzed by
one-way analysis of variance (ANOVA) followed by Tukey’s
test comparing samples treated with the same dose of
chemotherapeutic agent in HG vs. G condition. Statistical
significance level was set at p = 0.05.
RESULTS
Hyperglycemia Protected Against the
Decreased Cell Viability and Cytotoxicity
Induced by DOX and 5-FU
The cell viability, measured by neutral red uptake assay,
was significantly higher in HT29 and LOVO cells cultured
in HG compared with control cells at the same doses and
time incubation of DOX (Figures 1A,C,E,G) or of 5-FU
(Figures 2A,C). Only in euglycemic condition, DOX at 0.5 µM
for 48 h (Figures 1A,E) or DOX at 5 µM for 24 h (Figures 1C,G,
respectively, in HT29 and LOVO cells) and 5-FU at 25 µM
for 72 h (Figures 2A,C, respectively, in HT29 and LOVO
cells) were able to inhibit cell viability by 50%. Moreover, the
extracellular release of the intracellular enzyme LDH, used as
an index of cytotoxicity, was significantly lower in HT29 and
LOVO cells cultured in HG compared with control cells at the
same doses and time incubation of DOX (Figures 1B,D,F,H) or
of 5-FU (Figures 2B,D), whereas, in our experimental conditions,
hyperglycemia alone did not shown any cytotoxic effect. Given
the superimposable data of cell viability and LDH leakage, the
experimental conditions were standardized using DOX at 5 and
10 µM for 24 h and 5-FU at 25 and 50 µM for 72 h.
As anticancer drugs, DOX (Carlisi et al., 2017) and 5-FU (Hu
et al., 2016) were shown to have important cytotoxic effects on
tumor cells through ROS production, we analyzed the levels of
mitochondrial ROS, the main source of cellular ROS. We found
the ROS levels to be significantly lower after bolus of 5 and 10
µM DOX for 24 h and 25 and 50 µM 5-FU for 72 h in HT29
(Figures 3A,B) and LOVO cells (Figures 3C,D) cultured in HG
compared with control cells. No change in total cellular ROS were
found (data not shown).
Hyperglycemia Preserved the Integrity of
Mitochondrial DNA Induced by DOX and
5-FU in HT29 and LOVO Cells
The integrity maintaining of the mitochondrial genome
(mtDNA) is a prerequisite for proper mitochondrial function
(Yakes and Van Houten, 1997). Due to the high concentration
of mitochondrial ROS production induced by DOX or 5-FU
as shown in Figure 3, mtDNA could be strongly exposed
to oxidative stress, leading to mitochondrial DNA lesions.
Therefore, mtDNA damage analysis was performed to investigate
if a hyperglycemic condition, by lowering the levels of ROS
induced by DOX and 5-FU, could also prevent the effect of the
chemotherapeutic agents on mtDNA genome. We evaluated both
the mtDNA integrity and the lesion rate in the four following
different regions: (a) ATP-ase; (b) D-loop, (c) ND1/2, and (d)
ND4/5. (a) and (b) are well known sites of oxidative stress
damage (Rothfuss et al., 2010). We observed that in euglycemia
DOX 5 and 10µM 24 h significantly decreased the integrity of the
mtDNA in a dose dependent manner, whereas in hyperglycemia
only DOX 10 µM slightly decreased the integrity in HT29 and
LOVO cells (Figures 4A,C). Furthermore, in euglycemia DOX
5 and 10 µM 24 h significantly increased the lesion rate in
D-loop and encoding ATPase synthesis regions (5- and 10-fold
increase, respectively), whereas in hyperglycemia the increase
was only about 2.5 and 5 times, respectively (Figures 4B,D
- I,II). Superimposable data were obtained when HT29 and
LOVO cells were treated with 5-FU (data not shown). Once
again, in our experimental conditions, hyperglycemia reduces
the adverse effects of DOX and 5-FU by preserving the integrity
of mitochondrial damage.
Hyperglycemia Modified the MRP-1
Expression and Activity in LOVO Cells,
but Not in HT29 Cells
We then analyzed the effect of hyperglycemic condition on
the expression and activity of the ABC transporters. In HT29
cells cultured in G or HG the amount of intracellular DOX
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FIGURE 1 | Effect of normal glucose (G) and high glucose (HG) on cell proliferation and on LDH release from cells in the supernatant in absence or presence of
doxorubicin (DOX) in human colon cancer (HT29 and LOVO) cells. Cells were cultured for ≥7 days in the presence of G and HG, then subjected to the following
investigations. (A) Cells were left untreated or incubated for 48 h in the presence of different concentrations (0.05 µM, 0.1 µM, 0.5 µM, 1 µM, 2.5 µM) of DOX (A,E)
or 24 h in the presence of different concentrations (2.5 µM, 5 µM, 10 µM) of DOX (C,G). Samples were then stained in quadruplicate with the neutral red solution
(n = 4) to assess cell viability. IC50 was calculated as the concentration of DOX that kills 50% (dotted line) of cells. ∗p < 0.01 0.5, 1, 2.5, 5, and 10 µM DOX in
(Continued)
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FIGURE 1 | Continued
HT29/LOVO cells cultured in G vs. 0 µM DOX in HT29/LOVO cells cultured in G; ••p < 0.001 0.05, 0.1, 0.5, 1, 2.5, 5, and 10 µM DOX in HT29/LOVO cells cultured
in HG, respectively, vs. 0.05, 0.1, 0.5, 1, 2.5, 5, and 10 µM DOX in HT29/LOVO cells cultured in G. (B) Cells were left untreated or incubated for 48 h before analysis
with 0.5 µM and 1 µM of DOX (B,F) or for 24 h with 5 µM and 10 µM of DOX (D,H), then the LDH activity was measured. Extracellular LDH activity was calculated
as total (intracellular and extracellular) LDH activity in the dish. Measurements (n = 8) were performed in duplicate. ∗∗∗p < 0.0001 0.5, 1, 5, and 10 µM DOX in
HT29/LOVO cells cultured in G vs. 0 µM DOX in HT29/LOVO cells cultured in G; •••p < 0.0001 0.5, 1, 5, and 10 µM DOX in HT29/LOVO cells cultured in HG vs. 0
µM DOX in HT29/LOVO cells cultured in HG; ◦◦p < 0.001 1 µM DOX in HT29/LOVO cells cultured in HG vs. 0 µM DOX in HT29/LOVO cells cultured in HG;
◦◦p < 0.001 and ◦p < 0.002, respectively, 0.5, 1, 5, and 10 µM DOX in HT29/LOVO cells cultured in HG vs. 0.5, 1, 5, and 10 µM DOX in HT29/LOVO cells cultured
in G; § p < 0.002 0 µM DOX in LOVO cells cultured in HG vs. 0 µM DOX in LOVO cells cultured in HG.
FIGURE 2 | Effect of normal glucose (G) and high glucose (HG) on cell proliferation and on LDH release from cells in the supernatant in absence or presence of
5-fluorouracil (5-FU) in human colon cancer (HT29 and LOVO) cells. Cells were cultured for ≥7 days in the presence of G and HG, then subjected to the following
investigations. (A) Cells were left untreated or incubated for 72 h in the presence of different concentrations (1 µM, 5 µM, 10 µM, 25 µM, 50 µM) of 5-FU (A,C).
Samples were then stained in quadruplicate with the neutral red solution (n = 4) to assess cell viability. IC50 was calculated as the concentration of 5-FU that kills
50% (dotted line) of cells. ∗p < 0.01 25 and 50 µM 5-FU in HT29/LOVO cells cultured in G vs. 0 µM 5-FU in HT29/LOVO cells cultured in G; ••p < 1, 5, 10, 25, 50
5-FU in HT29/LOVO cells cultured in HG, respectively, vs. 1, 5, 10, 25, 50 5-FU in HT29/LOVO cells cultured in G. (B) Cells were left untreated or incubated for 72 h
with 25 µM and 50 µM of 5-FU (B,D), then the LDH activity was measured. Measurements (n = 8) were performed in duplicate. ∗∗∗p < 0.0001 25 and 50 µM 5-FU
in HT29/LOVO cells cultured in G vs. 0 µM 5-FU in HT29/LOVO cells cultured in G; ∗∗p < 0.001 25 µM 5-FU in HT29 cells cultured in G vs. 0 µM 5-FU in HT29 cells
cultured in G; •••p < 0.0001 25 and 50 µM 5-FU in LOVO cells cultured in HG vs. 0 µM 5-FU in LOVO cells cultured in G; ••p < 0.001 25 and 50 µM 5-FU in HT29
cells cultured in HG vs. 0 µM 5-FU in HT29 cells cultured in G; ◦◦p < 0.001 25 and 50 µM 5-FU in HT29/LOVO cells cultured in HG vs. 25 and 50 µM 5-FU in HT29
cells cultured in G; ◦p < 0.002, 25 µM 5-FU in HT29 cells cultured in HG vs. 25 µM 5-FU in HT29 cells cultured in G.
(Figure 5A), analyzed spectrophotometrically, and the nuclear
localization of DOX (data not shown), observed by fluorescent
microscopy, were similar. These data were confirmed by HPLC
analysis of cellular extracts that did not detect differences both in
the intracellular content of DOX and its metabolite doxorubicinol
(data not shown). At the opposite in LOVO cells, the amount of
intracellular DOX (Figure 5B) was significantly decreased after
24 h incubation with 5 and 10 µM DOX in HG condition.
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FIGURE 3 | Effect of normal glucose (G) and high glucose (HG) on mitochondrial ROS production in absence or presence of DOX (A,C) or 5-FU (B,D) in human
colon cancer (HT29 and LOVO) cells. Cells were cultured for ≥7 days in the presence of G and HG, incubated for 24 h before analysis with 5 and 10 µM DOX or 25
and 50 µM 5-FU and then the mitochondrial ROS levels were measured fluorimetrically in triplicate using the DCFDA-AM probe. Measurements (n = 8) were
performed in duplicate. (A) ∗∗∗p < 0.0001 5 and 10 µM DOX in HT29 cells cultured in G vs. 0 µM DOX in HT29 cells cultured in G; ◦◦◦p < 0.0001 5 and 10 µM
DOX in HT29 cells cultured in HG vs. 5 and 10 µM DOX in HT29 cells cultured in G; •••p < 0.0001 5 and 10 µM DOX in HT29 cells cultured in HG vs. 0 µM DOX in
HT29 cells cultured in HG. (B) ∗∗∗p < 0.0001 25 and 50 µM 5-FU in HT29 cells cultured in G vs. 0 µM 5-FU in HT29 cells cultured in G; ◦◦p < 0.001 25 and
◦◦◦p < 0.0001 50 µM 5-FU in HT29 cells cultured in HG vs. 25 and 50 µM 5-FU in HT29 cells cultured in G; ••p < 0.001 25 and •••p < 0.0001 50 µM 5-FU in
HT29 cells cultured in HG vs. 0 µM 5-FU in HT29 cells cultured in HG. (C) ∗∗∗p < 0.0001 5 and 10 µM DOX in LOVO cells cultured in G vs. 0 µM DOX in HT29 cells
cultured in G; ◦◦p < 0.001 5 and 10 µM DOX in HT29 cells cultured in HG vs. 5 and 10 µM DOX in LOVO cells cultured in G; ••p < 0.001 5 and 10 µM DOX in
LOVO cells cultured in HG vs. 0 µM DOX in HT29 cells cultured in HG. (D) ∗∗∗p < 0.0001 25 and 50 µM 5-FU in LOVO cells cultured in G vs. 0 µM 5-FU in LOVO
cells cultured in G; ◦◦◦p < 0.0001 25 and ◦◦p < 0.001 50 µM 5-FU in LOVO cells cultured in HG vs. 25 and 50 µM 5-FU in LOVO cells cultured in G; •••p < 0.0001
25 and ••p < 0.001 50 µM 5-FU in LOVO cells cultured in HG vs. 0 µM 5-FU in LOVO cells cultured in HG.
Moreover, in HT29 and LOVO cells after 72 h of incubation
with 25 and 50 µM 5-FU, the extracellular levels of 5-FU were
significantly higher in the supernatants of both HT29 and LOVO
cells cultured in HG condition: in HT29 cells, for 25 µM dose:
21.9 ± 1.07 in G vs. 25.9 ± 2.6 in HG and for 50 µM dose:
36.1± 1.3 in G vs. 48.1± 1.2) (Figure 6A), and in LOVO cells, for
25 µM dose: 10.0 ± 0.8 in G vs. 17.4 ± 0.9 in HG and for 50 µM
dose: 19.6± 0.6 in G vs. 25.6± 0.7) (Figure 6C). The intracellular
levels of 5-FU decreased in a time-dependent manner both in G
and HG conditions, but the levels were lower in HG condition
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FIGURE 4 | Effect of normal glucose (G) and high glucose (HG) on mitochondrial DNA damage (mtDNA) in absence or presence of DOX in human colon cancer
(HT29 and LOVO) cells. Cells were cultured for ≥7 days in the presence of G and HG, incubated for 24 h before analysis with 5 and 10 µM DOX, then washed and
processed to determine the mtDNA integrity by qRT-PCR and the lesion rate by semi-long run rt-PCR (SLR rt-PCR). Measurements (n = 6) were performed in
triplicate. (A) For mtDNA integrity measurements: ∗∗p < 0.001 and ∗∗∗p < 0.0001, respectively, 5 and or 10 µM DOX in HT29 cells cultured in G vs. 0 µM DOX in
HT29 cells cultured in G; ◦p < 0.00 10 µM DOX in HT29 cells cultured in HG vs. 0 µM DOX in HT29 cells cultured in HG; •••p < 0.0001 5 and or 10 µM DOX in
HT29 cells cultured in HG vs. 5 and or 10 µM DOX in HT29 cells cultured in G. (C) ∗∗∗p < 0.0001, 5 and or 10 µM DOX in LOVO cells cultured in G vs. 0 µM DOX in
LOVO cells cultured in G; ◦p < 0.00 10 µM DOX in LOVO cells cultured in HG vs. 0 µM DOX in LOVO cells cultured in HG; •••p < 0.0001 5 and or 10 µM DOX in
LOVO cells cultured in HG vs. 5 and or 10 µM DOX in LOVO cells cultured in G. (B,D) For lesion rate measurements: ∗∗p < 0.001 and ∗∗∗p < 0.0001, respectively,
5 and or 10 µM DOX in HT29/LOVO cells cultured in G vs. 0 µM DOX in HT29/LOVO cells cultured in G; § p < 0.01 0 µM DOX in HT29/LOVO cells cultured in HG
vs. 0 µM DOX in HT29/LOVO cells cultured in G; ◦p < 0.01 and ◦◦p < 0.001, respectively, 5 and 10 µM DOX in HT29/LOVO cells cultured in HG vs. 0 µM DOX in
HT29/LOVO cells cultured in HG; •• and •••p < 0.0001, respectively, 5 and or 10 µM DOX in HT29/LOVO cells cultured in HG vs. 5 and or 10 µM DOX in
HT29/LOVO cells cultured in G.
both in HT29 and LOVO cells (Figures 6B,D - I,II). Furthermore,
the intracellular levels of FdUMP, one of its active metabolite,
were similar in G and HG conditions (0.6 and 1 nmol/mg protein,
respectively).
To confirm that the protective effect of hyperglycemia
is independent of the intracellular amount of the
chemotherapeutics, we observed that in HT29 cells the amount
of intracellular of rhodamine 123, taken as an index of Pgp plus
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FIGURE 5 | Effect of normal glucose (G) and high glucose (HG) on intracellular accumulation of DOX in human colon cancer (HT29 and LOVO) cells. Cells were
cultured for ≥7 days in the presence of G and HG and incubated with 5 and 10 µM DOX for 24 h before analysis (A,B). The measurements were performed in
triplicate (n = 6). ∗∗p < 0.001 5 µM DOX in HT29 cells cultured in G and in HG vs. 0 µM DOX in HT29 cells cultured in G and in HG; ∗∗∗p < 0.0001 10 µM DOX in
HT29 cells cultured in G and in HG vs. 0 µM DOX in HT29/LOVO cells cultured in G and in HG; ∗∗∗p < 0.0001 5 and 10 µM DOX in HT29 cells cultured in G vs. 0
µM DOX in HT29 cells cultured in G; •••p < 0.0001 5 DOX in LOVO cells cultured in HG vs. 5 µM DOX in LOVO cells cultured in G; ••p < 0.001 10 DOX in LOVO
cells cultured in HG vs. 10 µM DOX in LOVO cells cultured in G.
FIGURE 6 | Effect of normal glucose (G) and high glucose (HG) on accumulation of 5-FU in human colon cancer HT29 and LOVO cells. Cells were cultured for ≥7
days in the presence of G and HG and incubated with 25 and 50 µM 5-FU for 72 h before analysis, then subjected to the following investigations. (A) The
extracellular content of 5-FU (A,C) was assessed by HPLC. The measurements were performed in duplicate and data are presented as mean ± SEM (n = 4).
∗p < 0.05 25 µM 5-FU in HT29 cells cultured in HG vs. G; ∗∗∗p < 0.0001 50 µM 5-FU in HT29 cells cultured in HG vs. G. ∗p < 0.05 25 µM 5-FU in LOVO cells
cultured in HG vs. G; ∗p < 0.05 50 µM 5-FU in LOVO cells cultured in HG vs. G. (B) The intracellular drug content of 5-FU (B,D) was assessed by HPLC-MS. The
measurements were performed in triplicate and data are presented as mean ± SEM (n = 3). At 25 µM 5-FU (B - I): ∗∗p < 0.001 in HT29 cells cultured in HG vs. G at
24 h; ∗p < 0.05 in HT29 cells cultured in HG vs. G at 48 h; ∗∗p < 0.001 in HT29 cells cultured in HG vs. G at 72 h. At 25 µM 5-FU (D - I): ∗∗p < 0.001 in LOVO cells
cultured in HG vs. G at 24 h; ∗p < 0.05 in LOVO cells cultured in HG vs. G at 48 h; ∗∗p < 0.001 in LOVO cells cultured in HG vs. G at 72 h. At 50 µM 5-FU (B - II):
∗∗p < 0.001 in HT29 cells cultured in HG vs. G at 24 h; ∗p < 0.05 in HT29 cells cultured in HG vs. G at 48 h; ∗p < 0.05 in HT29 cells cultured in HG vs. G at 72 h. At
50 µM 5-FU (D - II): ∗p < 0.05 in LOVO cells cultured in HG vs. G at 24 h; ∗∗p < 0.001 in LOVO cells cultured in HG vs. G at 48 h; ∗∗p < 0.001 in LOVO cells
cultured in HG vs. G at 72 h.
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FIGURE 7 | ATP binding cassette transporters activity (A,C) and levels of messenger RNA (mRNA) (B,D) of MDR-related proteins (such as BCRP and MRP1, 5 and
8) and P-glycoprotein (Pgp) genes in normal glucose (G) and high glucose (HG) in human colon cancer (HT29 and LOVO) cells. (A,C) Cells were cultured for ≥7 days
in the presence of G and HG, then washed and maintained for further 20 min at 37◦C in fresh medium or DBPS buffer, respectively, containing rhodamine 123 (to
assess Pgp and MRP activity) or Hoechst 33342 (to assess BCRP activity). The cells were lysed and the intracellular fluorescence, inversely related to its efflux, was
assessed fluorimetrically. Measurements (n = 6) were performed in triplicate. ∗∗p < 0.001 LOVO cells cultured in HG vs. LOVO cells cultured in G. (B,D) At the same
experimental conditions cells were analyzed by quantitative real-time polymerase chain reaction (RT-qPCR). Measurements (n = 6) were performed in triplicate, and
data, expressed as relative expression, are presented as means ± SEM; ∗p < 0.01 LOVO cells cultured in HG vs. LOVO cells cultured in G.
MRP activity, and Hoechst 33342, taken as an index of BCRP
activity (Figure 7A), and MRP1, 5 and 8, BCRP and Pgp gene
expression (Figure 7B) were not modified by HG incubation.
Otherwise, in LOVO cells only the amount of rhodamine 123
was significantly decreased (Figure 7C) as well as the MRP1 gene
expression were increased (Figure 7D).
These data showed that very HG alone, in our experimental
conditions, changed neither the intracellular accumulation of
DOX nor the expression of DOX and 5-FU-effluxing membrane
pumps in HT29 cells, but it decreased the amount of intracellular
DOX and 5-FU by increasing the activity of MRP1 through the
up regulation of MRP1 expression in LOVO cells.
According to these results, HG seemed to promote drug
chemoresistance in both HT29 and LOVO cells, but in a
different way. If the increased expression and activity of MRP1 in
LOVO cells cultured in HG could partially explain the decreased
intracellular amount of DOX, the effectiveness of DOX on HT29
cells cultured in HG is to be attributed to other molecular
mechanisms, among them changes in expression/function of
pro- and anti-apoptotic factors, defects in the cell cycle, and/or
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in expression/function of the molecular targets of anticancer
drugs, and enhanced ability of cancer cells to repair anticancer
drug-induced DNA damage (Meyerhardt et al., 2012).
Hyperglycemia Prevented the
Susceptibility to Apoptosis and
Diminished the Level of Cytosolic cyt c
and the Cleavage of Full Length of PARP
Induced by DOX and 5-FU in HT29 and
LOVO Cells
To verify the effect of hyperglycemia on ROS-mediated
mitochondrial pathway, we focused our attention on the
expression of pro- (Bax) and anti-apoptotic (Bcl-2 and Bcl-XL)
proteins that are involved not only in permeability of the outer
mitochondrial membrane, but also, through their effectors, in the
regulation of the cell cycle, DNA repair and replication (Donovan
and Cotter, 2004). The basal levels of Bcl-2 and Bcl-XL were
higher in HT29 (Figures 8, 9 and Supplementary Figures S1, S2)
and LOVO cells (Figures 10, 11 and Supplementary Figures S3,
S4) cultured in HG than that of cells cultured in normal
glucose. The addition of DOX at 5 and 10 µM for 24 h
and of 5-FU at 50 µM for 72 h down regulated much
more the expression of Bcl-2 and Bcl-XL in conditions of
euglycemia than in hyperglycemia in both HT29 and LOVO
cells. Moreover, the expression of Bax was completely absent
in HT29 cells cultured in HG in presence of 5 µM DOX
and very low in presence of 10 µM DOX (Figures 8,
9). Even if LOVO cells showed a higher basal level of
Bax, the addition of DOX at 5 and 10 µM for 24 h
upregulated the expression of Bax in conditions of euglycemia
and hyperglycemia (Figures 10, 11). In HT29 cells after
50 µM 5-FU incubation Bax expression was significantly
increased in G condition and very low in HG condition
(Supplementary Figures S1, S2), whereas in LOVO cells
this increase is abolished (Supplementary Figures S3, S4).
Considering the increase of the ratio Bax/Bcl-2 and Bax/Bcl-
XL as an indicator of susceptibility to apoptosis, in both
HT29 and LOVO cells, the state of hyperglycemia abolished
the pro-apoptotic effects of DOX and 5-FU by decreasing
the ratio Bax/Bcl-2 and Bax/Bcl-XL (Figures 9, 11 and
Supplementary Figures S2, S4).
Furthermore, there was a significant decrease in the release of
cytochrome c (cyt c) in the cytosol after bolus of DOX 5 and 10
µM and 5-FU 25 and 50 µM in HT29 and LOVO cells cultured
in HG. This data is in agreement with the decreased expression
of Bax, known mediator of the release of some factors, including
the cyt c, able to trigger apoptosis if they are located in the cytosol
(Figures 8–11 and Supplementary Figures S1–S4).
We next used Poly ADP-ribose polymerase (PARP) as caspase
activation index and as enzyme involved in DNA repair. In
hyperglycemia, we did not observe any enzymatic cleavage of full
length of PARP after DOX and 5-FU incubation of HT29 and
LOVO cells, whereas in euglycemia the presence of DOX for 24 h
and 5-FU for 72 h lead to a decrease (5 µM DOX, 25 µM 5-FU)
or disappearance (10 µM DOX, 50 µM 5-FU) of the full length
FIGURE 8 | Effect of normal glucose (G) and high glucose (HG) on Bcl-2,
Bcl-XL, Bax, PARP and cyt c protein expression in absence or presence of
DOX in human colon cancer HT29 cells. Cells were cultured for ≥7 days in the
presence of G and HG, incubated for 24 h before analysis with 5 and 10 µM
DOX, then washed and lysed. The level of GAPDH, used as an housekeeping
protein in total lysates, and the level of β-tubulin, used as an housekeeping
protein in mitochondrial lysates, were used to check the equal protein loading.
The figure is representative of three independent experiments.
PARP in HT29 cells (Figures 8, 9 and Supplementary Figures S1,
S2) and in LOVO cells (Figures 10, 11 and Supplementary
Figures S3, S4).
Hyperglycemia Reduced Cell Death by
Decreasing the Percentage of Cells in
Sub-G1 Peak Induced by DOX and 5-FU
in HT29 and LOVO Cells
As these anti-apoptotic factors are also involved in the regulation
of the cell cycle, we then performed experiments to evaluate cell
cycle in euglycemic and hyperglycemic conditions.
Cell cycle arrest in the G2/M phase, decrease of G0/G1
population and subsequent increase of cell percentage in sub-G1
induced by DOX was reverted by hyperglycemia
In HT29 and LOVO cells cultured in normal glucose the
24 h DOX treatment at 10 µM dose induced a significant
accumulation of the cells in the G2/M phase, demonstrating
inhibition of cell proliferation by cycle arrest in this phase,
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FIGURE 9 | Densitometry of Bcl-2, Bcl-XL, Bax, PARP, and cyt c protein expression in absence or presence of DOX in human colon cancer HT29 cells in G and HG
conditions. The protein bands of three independent experiments have been quantified by densitometry and the values are expressed as arbitrary units. (A) For Bcl-2
measurements: ∗∗p < 0.001 and ∗∗∗p < 0.0001 5 and 10 µM, respectively, DOX in HT29 cells cultured in G vs. 0 µM DOX in HT29 cells cultured in G; §§ p < 0.001
0 µM DOX in HT29 cells cultured in HG vs. 0 µM DOX in HT29 cells cultured in G; ◦p < 0.001 and ◦◦p < 0.0001 5 and 10 µM DOX in HT29 cells cultured in HG vs.
0 µM DOX in HT29 cells cultured in HG; ••p < 0.001 and •••p < 0.0001 5 and 10 µM DOX, respectively, in HT29 cells cultured in HG vs. 5 and 10 µM DOX,
respectively, DOX in HT29 cells cultured in G. (B) For Bcl-XL measurements: ∗∗∗p < 0.0001 and ∗∗p < 0.001 5 and 10 µM, respectively, DOX in HT29 cells cultured
in G vs. 0 µM DOX in HT29 cells cultured in G; §§ p < 0.001 0 µM DOX in HT29 cells cultured in HG vs. 0 µM DOX in HT29 cells cultured in G; ◦p < 0.001 and
◦◦p < 0.0001 5 and 10 µM DOX in HT29 cells cultured in HG vs. 0 µM DOX in HT29 cells cultured in HG; ?p < 0.01 10 µM DOX in HT29 cells cultured in HG vs. 10
µM DOX in HT29 cells cultured in G. (C) For Bax measurements: ∗∗∗p < 0.0001 and ∗∗p < 0.001 5 and 10 µM, respectively, DOX in HT29 cells cultured in G vs. 0
µM DOX in HT29 cells cultured in G; ◦p < 0.001 and ◦◦◦p < 0.0001 5 and 10 µM DOX in HT29 cells cultured in HG vs. 0 µM DOX in HT29 cells cultured in HG;
?p < 0.001 and ••p < 0.001 and •••p < 0.0001 5 and 10 µM DOX, respectively, in HT29 cells cultured in HG vs. 5 and 10 µM DOX, respectively, DOX in HT29 cells
cultured in G. (D) For Bax/Bcl-2 ratio measurements: ∗p < 0.001 and ∗∗∗p < 0.0001 5 and 10 µM, respectively, DOX in HT29 cells cultured in G vs. 0 µM DOX in
HT29 cells cultured in G; ?p < 0.001 and •••p < 0.0001 5 and 10 µM, respectively, DOX in HT29 cells cultured in HG vs. 5 and 10 µM DOX in HT29 cells cultured in
G. (E) For Bax/Bcl-XL ratio measurements: ∗p < 0.01 and ∗∗∗p < 0.0001, respectively, 5 and or 10 µM DOX in HT29 cells cultured in G vs. 0 µM DOX in HT29 cells
cultured in G; ?p < 0.001 and •••p < 0.0001, respectively, 5 and or 10 µM DOX in HT29 cells cultured in HG vs. 5 and or 10 µM DOX in HT29 cells cultured in G.
(F) For full length PARP measurements: ∗∗∗p < 0.0001 10 µM DOX in HT29 cells cultured in G vs. 0 µM DOX in HT29 cells cultured in G; §§ p < 0.001 0 µM DOX in
HT29 cells cultured in HG vs. 0 µM DOX in HT29 cells cultured in G. (H) For cit cyt c measurements: ∗∗∗p < 0.0001 5 and 10 µM, respectively, DOX in HT29 cells
cultured in G vs. 0 µM DOX in HT29 cells cultured in G; ◦◦p < 0.001 5 and 10 µM DOX in HT29 cells cultured in HG vs. 0 µM DOX in HT29 cells cultured in HG;
••p < 0.0001 5 and 10 µM DOX, respectively, in HT29 cells cultured in HG vs. 5 and 10 µM DOX, respectively, DOX in HT29 cells cultured in G. (G,I) For GAPDH
and β-tubulin measurements: n.s.
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FIGURE 10 | Effect of normal glucose (G) and high glucose (HG) on Bcl-2,
Bcl-XL, Bax, PARP and cyt c protein expression in absence or presence of
DOX in human colon cancer LOVO cells. Cells were cultured for ≥7 days in
the presence of G and HG, incubated for 24 h before analysis with 5 and 10
µM DOX, then washed and lysed. The level of GAPDH, used as an
housekeeping protein in total lysates, and the level of β-tubulin, used as an
housekeeping protein in mitochondrial lysates, were used to check the equal
protein loading. The figure is representative of three independent experiments.
accompanied by a corresponding decrease of G0/G1 population,
and causing cell death as shown by an increase in the percentage
of cells in sub-G1 peak (Figures 12A,C). At 5 and 10 µM DOX in
G condition, we assisted at a significant increase of percentage of
cells in sub-G1 compared to HG condition. Moreover, the DOX
treatment in HG condition did not influence the percentage of
cells in G0/G1, S and G2/M.
Cell cycle arrest in the S phase, decrease of G0/G1 population
and subsequent increase of cell percentage in sub-G1 induced by
5-FU and its metabolites was reverted by hyperglycemia
In HT29 and LOVO cells cultured in normal glucose a 72 h
treatment with 50 µM 5-FU led to a significant increase in the
percentage of cells in S-phase suggesting a strong cell cycle arrest
in this phase and a corresponding significant decrease of G0/G1
population, accompanied by a significant increase of sub-G1 cell
death population (Figures 12B,D). Moreover, this latter effect
was visible also in cells incubated with 25 µM 5-FU. On the
opposite, the 5-FU treatment in HG condition did not influence
the percentage of cells in G0/G1, S and G2/M and the percentage
of cell death is significantly lower at 50 µM compared to G
condition, even if at this concentration the percentage of cells in
sub-G1 peak remained significantly increased compared to HG
condition in the absence of 5-FU.
Hyperglycemia Lowered the Expression
and Activity of Topoisomerase
Abrogating the Action of DOX
As DOX could act as an intercalating agent of DNA synthesis
blocking its transcription and inhibiting the nuclear enzyme
topoisomerase activity of type II (Topo II alpha), we evaluated
the effect of hyperglycemia on the Topo II alpha expression
and activity. The RT-PCR results showed that hyperglycemia
decreased the expression of TOPO II alpha mRNA both in HT29
and LOVO cells (Figures 13A,B). Moreover, we tested the activity
of the topoisomerase II which, if presents in the nuclear lysate, is
able to decatenate, in the presence of ATP, the kDNA (catenate
DNA provided in the Topoisomerase II Assay Kit as a substrate
of the reaction) in decatenated DNAs that migrate rapidly into an
agarose gel.
In HT29 and LOVO cells (Figures 14A,B), the activity of
topoisomerase II, corresponding to a higher decatenation of
kDNA, after 24 h incubation of DOX 5 and 10 µM, is completely
inhibited in euglycemia. In hyperglycemia this activity was lower
in absence of DOX, due to a decrease of the expression of TOPO
II alpha mRNA, and 24 h incubation of DOX did not anymore
affect enzymatic activity.
DISCUSSION
Many epidemiological data clearly indicate that the risk of several
types of cancer is increased in diabetic patients and a number
of cancer types have shown a higher mortality rate in patients
with hyperglycemic associated pathologies (Vasconcelos-Dos-
Santos et al., 2017), even if less is known about the effect of
hyperglycemia on the response to the treatment of cancer.
Nowadays, some studies show that hyperglycemia confers
resistance to drug-induced cell death in different cancer cells
through different mechanisms. Garufi and D’ Oraz (2014) has
reported that a high blood glucose condition negatively affects
tumor response to therapies through the specific inhibition
of p53 – Ser 46 phosphorylation thus reducing p53 apoptotic
activity in colon, lung and ovarian cancer cell lines treated with
chemotherapeutic agents; Zeng et al. (2010) has shown that
hyperglycemia reduces the efficacy of chemotherapeutic drugs in
malignant breast epithelial cells through the activation of the fatty
acid synthase (FAS), enzyme responsible for the de novo synthesis
of fatty acids from sugars and the expression of which positively
correlates with aggressive tumors and poorer prognoses in
various cancers (Kuhajda, 2000). Biernacka et al. (2013) has
demonstrated the importance of metabolic environment in
reversible epigenetic modifications to genes that affect treatment
efficacy as increased glucose concentrations inhibits the efficacy
of docetaxel at inducing apoptosis in prostate cancer cell lines
by an increase of IGF-binding protein 2 (IGFBP2) production,
as a result of glucose-induced acetylation of histones bound
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FIGURE 11 | Densitometry of Bcl-2, Bcl-XL, Bax, PARP and cyt c protein expression in absence or presence of DOX in human colon cancer LOVO cells in G and
HG conditions. The protein bands of three independent experiments have been quantified by densitometry and the values are expressed as arbitrary units. (A) For
Bcl-2 measurements: ∗∗∗p < 0.0001 and ∗∗p < 0.001 5 and 10 µM, respectively, DOX in HT29 cells cultured in G vs. 0 µM DOX in HT29 cells cultured in G;
•••p < 0.0001 5 and 10 µM DOX, respectively, in HT29 cells cultured in HG vs. 5 and 10 µM DOX, respectively, DOX in HT29 cells cultured in G. (B) For Bcl-XL
measurements: ∗∗∗p < 0.0001 5 and 10 µM, respectively, DOX in HT29 cells cultured in G vs. 0 µM DOX in HT29 cells cultured in G; §§ p < 0.001 0 µM DOX in
HT29 cells cultured in HG vs. 0 µM DOX in HT29 cells cultured in G; ◦p < 0.001 5 and 10 µM DOX in HT29 cells cultured in HG vs. 0 µM DOX in HT29 cells
cultured in HG; •••p < 0.0001 5 and 10 µM DOX in HT29 cells cultured in HG vs. 5 and 10 µM DOX in HT29 cells cultured in G. (C) For Bax measurements:
∗∗∗p < 0.0001 5 and 10 µM, respectively, DOX in HT29 cells cultured in G vs. 0 µM DOX in HT29 cells cultured in G; §§ p < 0.001 0 µM DOX in HT29 cells cultured
in HG vs. 0 µM DOX in HT29 cells cultured in G; ◦◦◦p < 0.0001 and ◦◦p < 0.001 5 and 10 µM DOX in HT29 cells cultured in HG vs. 0 µM DOX in HT29 cells
cultured in HG; •••p < 0.0001 5 and 10 µM DOX, respectively, in HT29 cells cultured in HG vs. 5 and 10 µM DOX, respectively, DOX in HT29 cells cultured in G. (D)
For Bax/Bcl-2 ratio measurements: ∗∗∗p < 0.0001 5 and 10 µM, respectively, DOX in HT29 cells cultured in G vs. 0 µM DOX in HT29 cells cultured in G; §§
p < 0.001 0 µM DOX in HT29 cells cultured in HG vs. 0 µM DOX in HT29 cells cultured in G; ◦◦◦p < 0.001 5 and 10 µM DOX in HT29 cells cultured in HG vs. 0 µM
DOX in HT29 cells cultured in HG; •••p < 0.0001 5 and 10 µM, respectively, DOX in HT29 cells cultured in HG vs. 5 and 10 µM DOX in HT29 cells cultured in G. (E)
For Bax/Bcl-XL ratio measurements: ∗p < 0.01 and ∗∗∗p < 0.0001, respectively, 5 and or 10 µM DOX in HT29 cells cultured in G vs. 0 µM DOX in HT29 cells
cultured in G; §§ p < 0.001 0 µM DOX in HT29 cells cultured in HG vs. 0 µM DOX in HT29 cells cultured in G; ◦◦p < 0.001 5 and 10 µM DOX in HT29 cells cultured
in HG vs. 0 µM DOX in HT29 cells cultured in HG; •••p < 0.0001, respectively, 5 and or 10 µM DOX in HT29 cells cultured in HG vs. 5 and or 10 µM DOX in HT29
cells cultured in G. (F) For full length PARP measurements: ∗∗p < 0.001 5 and 10 µM, respectively, DOX in HT29 cells cultured in G vs. 0 µM DOX in HT29 cells
cultured in G; § p <0.01 0 µM DOX in HT29 cells cultured in HG vs. 0 µM DOX in HT29 cells cultured in G. (H) For cit cyt c measurements: ∗∗∗p < 0.0001 5 and 10
µM, respectively, DOX in HT29 cells cultured in G vs. 0 µM DOX in HT29 cells cultured in G; •••p < 0.0001 5 and 10 µM DOX, respectively, in HT29 cells cultured in
HG vs. 5 and 10 µM DOX, respectively, DOX in HT29 cells cultured in G. (G,I) For GAPDH and β-tubulin measurements: n.s.
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FIGURE 12 | Effect of normal glucose (G) and high glucose (HG) on cell cycle in HT29 and LOVO cells in absence or presence of DOX (A,C) or 5-FU (B,D). Cells
were cultured for ≥7 days in the presence of G and HG, incubated for 24 h before analysis with 5 and 10 µM DOX (A,C) or for 72 h with 25 and 50 µM 5-FU (B,D)
and then cells were analyzed for DNA content by FACS analysis. Panels represent the distribution of cells in different phases of cell cycle. Measurements (n = 3) were
performed and data are presented as means ± SEM. (A,C) ∗p < 0.01 5 and 10 µM DOX in HT29 cells cultured in G vs. 0 µM DOX in HT29 cells cultured in G; §
p < 0.01 10 µM DOX in HT29 cells cultured in HG vs. 0 µM DOX in HT29 cells cultured in HG; #p <0.01 5 and 10 µM DOX in HT29 cells cultured in HG vs. 5 and
10 µM DOX in HT29 cells cultured in G. (B,D) ∗p < 0.01 and ∗∗p < 0.001 25 and 50 µM 5-FU in HT29 cells cultured in G vs. 0 µM 5-FU in HT29 cells cultured in G;
§ p < 0.01 50 µM 5-FU in HT29 cells cultured in HG vs. 0 µM 5-FU in HT29 cells cultured in HG; #p < 0.01 50 µM 5-FU in HT29 cells cultured in HG vs. 50 µM
5-FU in HT29 cells cultured in G.
to the IGFBP2 promoter; Shao et al. (2014) has demonstrated
that high concentrations of glucose suppress etoposide-induced
cell death of B-cell lymphoma by inducing the transcription
factor BCL-6 that acts as a transcriptional repressor of
etoposide-induced apoptosis via the caspase pathway. Moreover,
Ma et al. (2014) has determined that HG treatment diminishes
the antiproliferative effect of 5-FU on colon cancer cells by
decreasing cell death and increasing DNA replication, suggesting
that in diabetic patients with colorectal cancer a higher dosage
and duration of 5-FU treatment is required to inhibit the growth
of tumor cells adequately. More recently, Ikemura and Hashida
(2017) has reported that anticancer agents oxaliplatin and 5-FU
administered to streptozotocin (STZ)-treated hyperglycemic
mice are less effective and their survival is shorter compared to
STZ-treated euglycemic mice.
ROS may play dual role in cancer progression in a dose-
dependent manner. On the one hand, mild intracellular ROS
can stimulate tumor progression by promoting cell proliferation,
survival, invasion and metastasis; on the other hand, excess ROS
production can cause oxidative damage and trigger cancer cell
death (Nishikawa et al., 2009). Indeed it has been observed that
HG levels increased ROS production by activating both p38
MAPK and ERK pathways (Li et al., 2014), and by stimulating cell
proliferation, migration and invasion (Flores-López et al., 2016),
respectively, in pancreatic and breast cancer cells. In contrast,
as known, chemotherapeutic agents inducing an oxidative stress
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FIGURE 13 | Effect of normal glucose (G) and high glucose (HG) on mRNA
expression and in absence or presence of DOX in human colon cancer (HT29
(A) and LOVO (B)) cells. Cells were cultured for ≥7 days in the presence of G
and HG, then washed and processed to determine the Topoisomerase II
mRNA expression. The figure is representative of three independent
experiments. Cells were analyzed by quantitative real-time polymerase chain
reaction (RT-qPCR). Measurements (n = 6) were performed in triplicate, and
data are expressed as relative expression; (A) ∗p < 0.01 HT29 cells cultured
in HG vs. HT29 cells cultured in G and (B) ∗p < 0.01 LOVO cells cultured in
HG vs. LOVO cells cultured in G.
status cause mitochondrial respiratory chain ROS generation
(Victorino et al., 2014) that play a significant role in the
inhibition of cancer progression (Trachootham et al., 2009).
Moreover, due to the high reactive environment, and probably to
a mitochondrial chromatin-like structure condensed to a lesser
extent than nuclear chromatin, the mtDNA is frequently exposed
to oxidative stress leading to mitochondrial genomic defects and
any damage within the electron transport system (Yakes and
Van Houten, 1997). Thus, these alterations in mitochondrial
physiology may contribute to a cellular stress response, cell
growth arrest, and subsequent apoptosis (Rothfuss et al., 2010).
For the first time, we demonstrate that a prolonged HG
exposure protects human colon adenocarcinoma HT29 and
LOVO cells against the decreased cell viability and cytotoxicity
by, at least partly, lowering mitochondrial ROS production
induced by DOX and 5-FU, thus impairing the effectiveness of the
chemotherapy itself. Moreover, our results provide support for
the role of mitochondrial derived ROS drug-induced in mtDNA
damage during G growth condition, whereas under HG exposure,
the small amount of generated ROS within the mitochondria
leads to a low level of mtDNA damage in the D-loop and ATPase6
regions.
In addition to this evidence, as we could not exclude that
HG exposure also acted on the onset of MDR through the
overexpression of ABC transporters, we investigated whether
FIGURE 14 | Effect of normal glucose (G) and high glucose (HG) on
Topoisomerase II alpha activity in absence or presence of DOX in human
colon cancer (HT29 (A) and LOVO (B)) cells. Cells were cultured for ≥7 days
in the presence of G and HG, incubated for 24 h before analysis with 5 and 10
µM DOX, then washed and processed to determine the nuclear
Topoisomerase II catalytic activity. The figure is representative of three
independent experiments. The nuclear Topo II alpha activity is represented by
the reduction of catenated kDNA provided in TopoGEN assay kit and/or the
appearance of decatenated kDNA.
the effect of hyperglycemia on the decreased cell viability and
cytotoxicity induced by DOX and 5-FU may be explained by a
change in the expression and activity of Pgp and/or the MDR-
related proteins, among which MRP1, 5 and 8, and BCRP. We do
not observe any difference neither in the amount of intracellular
content of DOX and their metabolites nor in the localization
of DOX when HT29 cells are cultured in G or HG conditions.
In agreement with these results, we observe that in HT29 cells
the amount of intracellular of rhodamine 123, taken as an index
of Pgp plus MRP activity, and Hoechst 33342, taken as an
index of BCRP activity, and MRP1, 5 and 8, BCRP and Pgp
gene expression are not modified by HG incubation in HT29
cells. However, in LOVO cells, we observe that HG exposure
decreases the amount of intracellular DOX, increasing the activity
of MRP1 through the up regulation of MRP1 expression. These
latter data with the results obtained in a murine tumor model
in which glucose-exposed tumor cells of late tumor-bearing
stage show a declined susceptibility to the cytotoxic action
of cisplatin and methotrexate, accompanied by an increased
expression of MDR-1 gene (Vishvakarma et al., 2013). Moreover
our results totally deviate from the study of Pandey et al. (2011)
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in which it has been reported that hyperglycemia potentiates the
cytotoxicity of carboplatin- and 5-FU-treated breast cells cultured
in HG by increasing ROS levels and reducing the expression
of P-glycoprotein that promotes cell killing by increasing drug
accumulation. Seebacher et al. (2015) suggested that, in small cell
lung and cervical carcinoma cell lines, glucose deprivation or HG
induce stress, increasing HIF-1α and leading to a more aggressive
MDR phenotype via up-regulation of Pgp.
At this stage, we have no explanation on why HG induces
drug chemo-resistance in a different manner in HT29 and
LOVO cells. Nevertheless, if the effect of HG in LOVO cells
on the response to chemotherapeutic drugs seems to follow
a well-honed mechanism, the effectiveness of DOX and 5-FU
on HT29 cells cultured in HG is to be attributed to other
molecular mechanisms, independent from the overexpression
ABC transporters, among them changes in expression/function
of pro- and anti-apoptotic factors, defects in the cell cycle, and/or
in expression/function of the molecular targets of anticancer
drugs and enhanced ability of cancer cells to repair anticancer
drug-induced DNA damage (Meyerhardt et al., 2003).
As is the case with most of the chemotherapeutic agents,
multiple mechanisms have been implicated in the development
of drugs resistance, including elevated levels of anti-apoptotic
genes, alterations in permeability of the outer mitochondrial
membrane and through their effectors in the regulation of the
cell cycle (Donovan and Cotter, 2004) and an increase in DNA
damage repair (Fojo and Bates, 2003). Apoptosis can be of two
types, one involving engagement of the death receptors and the
other with initiated and propagated by generation of ROS, and
consequently the release of cytochrome c from the mitochondria
(Samejima et al., 2001). The Bcl-2 protein is known to inhibit
apoptosis by regulating the mitochondrial membrane potential
1ψM and cytochrome c release needed for activation of caspase-
9 (Yoon et al., 2013). Panaretakis et al. (2002) reported that Bcl-2
overexpression protects against DOX-induced apoptosis through
blockage of the activation of Bad and Bax.
The intracellular effects of DOX include free radical
formation, activation of caspases, cleavage of Poly ADP-
ribose polymerase (PARP), inhibition of DNA topoisomerase
II and also nucleotide intercalation, resulting in inhibition
of DNA replication, presence of DNA fragmentation and
sub-diploid DNA content (Poornima et al., 2014). Recently,
Zhao et al. (2015) demonstrated that, in gastric cancer cells,
hyperglycemia may confer MDR at least partially by increasing
the nicotinamide phosphoribosyltransferase (Nampt) and the
silent information regulator 1 (Sirt1) expression, promoting
Pgp level and reducing Topo IIα expression. Zhao et al.
(2015) has reported that Topo II alpha mRNA expression
was higher compared with gastric cancer patients. Our data
demonstrated that hyperglycemia lowered the mRNA expression
and activity of Topo II alpha, thus abrogating the action
of DOX both in HT29 and LOVO colon adenocarcinoma
cells.
We therefore focus our attention on the expression of pro-
(Bax) and anti-apoptotic (Bcl-2 and Bcl-XL) proteins and, as
expected, we confirm that the state of hyperglycemia abolishes
the pro-apoptotic effects of DOX and 5-FU by decreasing, in
both HT29 and LOVO cells, the ratio Bax/Bcl-2 and Bax/Bcl-
XL, taken as an indicator of susceptibility to apoptosis. In
agreement with this, the release of cytochrome c in the
cytosol after bolus of DOX and 5-FU is decreased in HG
condition. Moreover, the basal level PARP, used as caspase
activation index and as enzyme involved in DNA repair, is
significantly higher in hyperglycemia and we did not observed
in this condition any enzymatic cleavage of full length of
PARP after DOX and 5-FU incubation of HT29 and LOVO
cells.
Kuznetsov et al. (2011) demonstrated that DOX inhibits
human colon and breast cancer cell proliferation through cell
cycle arrest at the G2/M phase in a time- and dose-dependent
manner, also causing massive cell death. The acquisition of drug
resistance of cancer cells is a major obstacle in cancer treatment
also due to differences in cell cycle modulation and progression.
In our study, we observed that in hyperglycemia there is
a significant lower percentage of cells in sub-G1 population
compared to G condition and the DOX and 5-FU treatment
in HG condition did not influence the percentage of cells in
G0/G1, S and G2/M, suggesting that hyperglycemia may modify
the DOX or 5-FU effect modulating the cyclin–dependent cell
growth checkpoint.
Three of the 5-FU intracellular formed nucleotides
metabolites, the 5-fluorouridine 5-triphosphate (FUTP),
the 5-fluoro-2-deoxyuridine 5-triphosphate (FdUTP), and
the 5-fluoro-2-deoxyuridine 5-monophosphate (FdUMP), are
responsible for the antineoplastic effect of 5-FU. In brief, FUTP
is incorporated into RNA and interferes with normal RNA
processing and function, FdUTP is incorporated into DNA,
leading to pathological DNA structures and ultimately cell death
and FdUMP acts during the S phase of the cell cycle inhibiting
DNA synthesis by restricting availability of thymidylate as
it inhibits the thymidylate synthetase (Derissen et al., 2015).
Moreover 5-FU increases ROS production which triggered the
mitochondria-caspase pathway of apoptosis (Hu et al., 2016).
Matuo et al. (2009) shown that 5-FU and FdUMP influenced
differently the cell cycle progression of human SW620 colon
adenocarcinoma cell line. Indeed, 5-FU induced a G1/S arrest,
while FdUMP led to a G2/M arrest. This different pattern of
cell cycle arrest suggests that the two drugs induce different
types of primary DNA lesions, leading to the activation of
different checkpoints and to the recruitment of different DNA
repair pathways (Matuo et al., 2009). In HT29 and LOVO
cells cultured in normal glucose, only after 72 h treatment
with 25 and 50 µM 5-FU, there is a significant increase in
the percentage of cells in S-phase suggesting a strong cell
cycle arrest in this phase and a corresponding significant
decrease of G0/G1 population, accompanied by a significant
increase of sub-G1 cell death population, LDH leakage and ROS
production. On the opposite, in HG condition 5-FU does not
influence the percentage of cells in G0/G1, S and G2/M and
that of cell death is significantly lower also at 50 µM compared
to G condition, accompanied by low levels of LDH leakage
and ROS. Moreover, our data show that also in G condition,
FdUMP does not have any effect on cell cycle arrest in G2/M,
probably due to its very low level of synthesis. Furthermore,
Frontiers in Pharmacology | www.frontiersin.org 20 August 2018 | Volume 9 | Article 866
fphar-09-00866 August 10, 2018 Time: 17:46 # 21
Bergandi et al. Hyperglycemia Promotes Chemoresistance
as there are no differences in the expression/activity of MRP5
and 8 between G and HG conditions, our data, confirmed
by the measurement of the intracellular amount of 5-FU,
suggest that the lack of 5-FU treatment effect in HG condition
is probably due to the lower entry of the drug into the
cells.
Taken together, these data bring further knowledge on the
molecular mechanisms involved in chemoresistance during
hyperglycemia. Indeed a prolonged exposure to HG protects
human colon adenocarcinoma cells from the cytotoxic effects
of two widely used chemotherapeutic drugs, impairing the
effectiveness of the chemotherapy itself.
This should elicit an even greater care in maintaining the
euglycemic state in pre- and diabetic oncological patients to
increase the success of chemotherapy, thus limiting the over dose
of the treatment with the subsequent side effects.
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FIGURE S1 | Effect of normal glucose (G) and high glucose (HG) on Bcl-2, Bcl-XL,
Bax, PARP, and cyt c protein expression in absence or presence of 5-FU in human
colon cancer HT29 cells. Cells were cultured for ≥7 days in the presence of G and
HG, incubated for 24 h before analysis with 25 and 50 µM 5-FU, then washed
and lysed. The level of GAPDH, used as an housekeeping protein in total lysates,
and the level of β-tubulin, used as an housekeeping protein in mitochondrial
lysates, were used to check the equal protein loading. The figure is representative
of two independent experiments.
FIGURE S2 | Densitometry of Bcl-2, Bcl-XL, Bax, PARP, and cyt c protein
expression in absence or presence of 5-FU in human colon cancer HT29 cells in G
and HG conditions. The protein bands of two independent experiments have been
quantified by densitometry and the values are expressed as arbitrary units. (A) For
Bcl-2 measurements: ∗∗p < 0.001 and ∗∗∗p < 0.0001 25 and 50 µM,
respectively, 5-FU in HT29 cells cultured in G vs. 0 µM 5-FU in HT29 cells cultured
in G; ••p < 0.001 50 µM 5-FU in HT29 cells cultured in HG vs. 50 µM 5-FU in
HT29 cells cultured in G. (B) For Bcl-XL measurements: ∗∗p < 0.001 25 and 50
µM, respectively, 5-FU in HT29 cells cultured in G vs. 0 µM 5-FU in HT29 cells
cultured in G; §§ p < 0.001 0 µM 5-FU in HT29 cells cultured in HG vs. 0 µM 5-FU
in HT29 cells cultured in G; ••p < 0.01 25 and 50 µM 5-FU in HT29 cells cultured
in HG vs. 25 and 50 µM 5-FU in HT29 cells cultured in G. (C) For Bax
measurements: ∗∗∗p < 0.0001 50 µM 5-FU in HT29 cells cultured in G vs. 0 µM
5-FU in HT29 cells cultured in G; § p < 0.001 0 µM 5-FU in HT29 cells cultured in
HG vs. 0 µM 5-FU in HT29 cells cultured in G; ◦p < 0.002 and ◦◦p < 0.001 25
and 50 µM, respectively, 5-FU in HT29 cells cultured in HG vs. 0 µM 5-FU X in
HT29 cells cultured in HG; ••p < 0.001 50 µM 5-FU in HT29 cells cultured in HG
vs. 50 µM 5-FU in HT29 cells cultured in G. (D) For Bax/Bcl-2 ratio
measurements: ∗p < 0.001 and ∗∗∗p < 0.0001 25 and 50 µM, respectively, 5-FU
in HT29 cells cultured in G vs. 0 µM 5-FU in HT29 cells cultured in G; ••p < 0.001
50 µM 5-FU in HT29 cells cultured in HG vs. 50 µM 5-FU in HT29 cells cultured in
G. (E) For Bax/Bcl-XL ratio measurements: ∗p < 0.01 and ∗∗∗p < 0.001,
respectively, 25 and or 50 µM 5-FU in HT29 cells cultured in G vs. 0 µM 5-FU in
HT29 cells cultured in G; § p < 0.001 0 µM 5-FU in HT29 cells cultured in HG vs.
0 µM 5-FU in HT29 cells cultured in G; ••p < 0.001 and •••p < 0.0001,
respectively, 25 and or 50 µM 5-FU in HT29 cells cultured in HG vs. 25 and or 50
µM 5-FU in HT29 cells cultured in G. (F) For full length PARP measurements:
∗∗p < 0.001 and ∗∗∗p < 0.0001 25 and 50 µM, respectively, 5-FU in HT29 cells
cultured in G vs. 0 µM 5-FU in HT29 cells cultured in G; ••p < 0.001 respectively,
25 and or 50 µM 5-FU in HT29 cells cultured in HG vs. 25 and or 50 µM 5-FU in
HT29 cells cultured in G. (H) For cit cyt c measurements: ∗∗∗p < 0.0001 25 and
50 µM, respectively, 5-FU in HT29 cells cultured in G vs. 0 µM 5-FU in HT29 cells
cultured in G; § p < 0.001 0 µM 5-FU in HT29 cells cultured in HG vs. 0 µM 5-FU
in HT29 cells cultured in G; ◦p < 0.001 25 and 50 µM 5-FU in HT29 cells cultured
in HG vs. 0 µM DOX in HT29 cells cultured in HG; ••p < 0.0001 25 and 50 µM
5-FU, respectively, in HT29 cells cultured in HG vs. 25 and 50 µM 5-FU,
respectively, DOX in HT29 cells cultured in G. (G,I) For GAPDH and β-tubulin
measurements: n.s.
FIGURE S3 | Effect of normal glucose (G) and high glucose (HG) on Bcl-2, Bcl-XL,
Bax, PARP, and cyt c protein expression in absence or presence of 5-FU (5-FU) in
human colon cancer LOVO cells. Cells were cultured for ≥7 days in the presence
of G and HG, incubated for 24 h before analysis with 25 and 50 µM 5-FU, then
washed and lysed. The level of GAPDH, used as an housekeeping protein in total
lysates, and the level of β-tubulin, used as an housekeeping protein in
mitochondrial lysates, were used to check the equal protein loading. The figure is
representative of three independent experiments.
FIGURE S4 | Densitometry of Bcl-2, Bcl-XL, Bax, PARP, and cyt c protein
expression in absence or presence of 5-FU in human colon cancer LOVO cells in
G and HG conditions. The protein bands of two independent experiments have
been quantified by densitometry and the values are expressed as arbitrary units.
(A) For Bcl-2 measurements: ∗p < 0.01 25 and 50 µM, respectively, 5-FU in HT29
cells cultured in G vs. 0 µM DOX in HT29 cells cultured in G; ••p < 0.001 and
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•••p < 0.0001 25 and 50 µM, respectively, 5-FU in HT29 cells cultured in HG vs.
25 and 50 µM, respectively, 5-FU in HT29 cells cultured in G. (B) For Bcl-XL
measurements: ∗∗∗p < 0.0001 50 µM 5-FU in HT29 cells cultured in G vs. 0 µM
5-FU in HT29 cells cultured in G; §§ p < 0.001 0 µM 5-FU in HT29 cells cultured in
HG vs. 0 µM 5-FU in HT29 cells cultured in G; ?p < 0.001 and ••p < 0.0001 25
and 50 µM, respectively, 5-FU in HT29 cells cultured in HG vs. 25 and 50 µM,
respectively, 5-FU in HT29 cells cultured in G. (C) For Bax measurements:
∗∗∗p < 0.0001 50 µM 5-FU in HT29 cells cultured in G vs. 0 µM 5-FU in HT29
cells cultured in G; •••p < 0.0001 50 µM 5-FU in HT29 cells cultured in HG vs. 50
µM 5-FU in HT29 cells cultured in G. (D) For Bax/Bcl-2 ratio measurements:
∗p < 0.01 and ∗∗∗p < 0.0001 25 and 50 µM, respectively, 5-FU in HT29 cells
cultured in G vs. 0 µM 5-FU in HT29 cells cultured in G; § p < 0.001 0 µM 5-FU in
HT29 cells cultured in HG vs. 0 µM 5-FU in HT29 cells cultured in G; ?p < 0.01
and •••p < 0.0001 25 and 50 µM, respectively, 5-FU in HT29 cells cultured in HG
vs. 25 and 50 µM, respectively, 5-FU in HT29 cells cultured in G. (E) For
Bax/Bcl-XL ratio measurements: ∗p < 0.01 and ∗∗∗p < 0.0001 25 and 50 µM,
respectively, 5-FU in HT29 cells cultured in G vs. 0 µM 5-FU in HT29 cells cultured
in G; § p < 0.001 0 µM 5-FU in HT29 cells cultured in HG vs. 0 µM 5-FU in HT29
cells cultured in G; ?p < 0.01 and •••p < 0.0001 25 and 50 µM, respectively,
5-FU in HT29 cells cultured in HG vs. 25 and 50 µM, respectively, 5-FU in HT29
cells cultured in G. (F) For full length PARP measurements: ∗∗p < 0.001 and
∗∗∗p < 0.0001 25 and 50 µM, respectively, 5-FU in HT29 cells cultured in G vs. 0
µM 5-FU in HT29 cells cultured in G; ••p < 0.001 0 µM 525 and 50 µM,
respectively, 5-FU in HT29 cells cultured in HG vs. 25 and 50 µM, respectively,
5-FU in HT29 cells cultured in G. (H) For cit cyt c measurements: ∗∗p < 0.001 and
∗∗∗p < 0.0001 25 and 50 µM, respectively, 5-FU in HT29 cells cultured in G vs. 0
µM 5-FU in HT29 cells cultured in G; ◦p < 0.001 25 and 50 µM, respectively,
5-FU in HT29 cells cultured in HG vs. 0 µM DOX in HT29 cells cultured in HG;
••p < 0.0001 25 and 50 µM, respectively, 5-FU in HT29 cells
cultured in HG vs. 25 and 50 µM, respectively, 5-FU in HT29
cells cultured in G. (G,I) For GAPDH and β-tubulin
measurements: n.s.
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